Emily Menendez

Emily Menendez is an assistant editor for GU Oncology Now and Cancer Nursing Today. She uses her copywriting experience to contribute content on the latest updates in the oncology nursing sphere. Ms. Menendez received her BA from the University of Central Florida.

Articles by Emily Menendez

Emily MenendezAdvanced Imaging | December 4, 2023
Clarity announced the second phase of the SECuRE trial's third cohort has commenced, as has the phase 3 CLARIFY trial.
Read More
Emily MenendezSUO 2023 | November 30, 2023
The NODESAFE model can aid in clinical decision-making and may spur consideration for adjuvant therapy in patients with RCC.
Emily MenendezSUO 2023 | November 30, 2023
Enzalutamide plus leuprolide acetate and enzalutamide alone caused delayed MFS when compared with placebo plus leuprolide.
Emily MenendezSUO 2023 | November 29, 2023
An in vitro model of EV-resistant bladder cancer showed that EV resistance was mainly due to resistance of the payload MMAE.
Emily MenendezSUO 2023 | November 29, 2023
Single-port and multi-port RARP approaches were found to provide similar 1-year biochemical recurrence rates.
Emily MenendezSUO 2023 | November 29, 2023
Similar to results from the intention-to-treat population, pembrolizumab was favored for its benefit of prolonging DFS.
Emily MenendezSUO 2023 | November 28, 2023
At SUO 2023, Dr. Nicholas Corsi, UT Southwestern, presented one of the largest multinational studies on NAC in UTUC to date.
Emily MenendezSUO 2023 | November 28, 2023
Almost half of all patients initiating 1L platinum-based chemotherapy were unable to receive maintenance avelumab treatment.
Emily MenendezUpper Tract Urothelial Carcinoma | November 21, 2023
The nomogram outperformed 2 conventional models in predictive accuracy and showed higher benefit in decision curve analysis.
Emily MenendezMuscle Invasive Urothelial Carcinoma | November 20, 2023
Pembrolizumab with CRT is a feasible treatment option for MIBC with promising CR rates and manageable toxicity.
Emily MenendezCRPC | November 20, 2023
Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age.
Emily MenendezProstate Cancer | November 20, 2023
There was a 57% increase in the number of non-European prostate cancer cases compared to previous association studies.
Emily Menendez2023 IKCS: North America | November 20, 2023
TKI monotherapy and TKI plus non-IO therapy was the most common subsequent treatment utilized after receiving IO-TKI.
Emily Menendez2023 IKCS: North America | November 20, 2023
Past 12 months, the effectiveness and safety between nivolumab plus ipilimumab and pembrolizumab plus axitinib were similar.
Emily Menendez2023 IKCS: North America | November 13, 2023
The TRAE rates of 1L nivolumab plus ipilimumab were low and remained consistent relative to clinical trials.
Emily Menendez2023 IKCS: North America | November 13, 2023
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Emily MenendezNon-Muscle Invasive Urothelial Carcinoma | November 10, 2023
Researchers sought to develop an NLP model to describe patients and tumor characteristics to more easily aggregate data.
Emily MenendezRLT | November 10, 2023
A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was found to be a safe treatment for mCRPC.
Emily MenendezLocalized | November 10, 2023
PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP.
Emily MenendezLocalized Renal Cell Carcinoma | November 8, 2023
The anti-PD-1 therapy met the trial’s key secondary endpoint of OS for patients with RCC following nephrectomy.